The final tournament of the UEFA European Football Championship is one of the top sporting events in the world, and a high-profile event of this kind requires a well-planned and well-executed anti-doping programme to ensure the integrity of results in the competition. UEFA EURO 2012 presented a unique logistical challenge, with the tournament spread across two countries, both covering a large geographical area. This paper discusses the planning and delivery of both the pre tournament out-of-competition (OOC) testing programme and the in-competition (IC) programme, as well as reviewing the activities of doping control officers (DCOs), the whereabouts programme and assessing the sample collection and transport process. The analytical approach applied is also discussed, along with an overview of the distribution of T/E ratios and blood parameters. 
Introduction
The final round of the UEFA European Football Championship is a tournament for the top national teams in European men's football and is held every four years. The 2012 tournament was contested by 16 teams, which reached the final round via a series of qualification matches held over the preceding two years. That tournament was the 14th to be staged by UEFA and the first to be staged in the neighbouring countries of Poland and Ukraine. The tournament began in Warsaw on 8 June 2012 and ended with the final in Kiev on 1 July 2012.
Teams listed in Table 1 qualified for the final tournament, and a total of 367 players were registered to take part (23 from each country, with the exception of one team that registered only 22 players) UEFA has many years of experience with the planning of in-and out-of-competition doping controls in elite football and operates an annual anti-doping programme for all of its national and club competitions. The programme uses an experienced team of doping control officers (DCOs), established sample transport procedures and a network of World Anti-Doping Agency (WADA)-accredited laboratories across Europe to ensure maximum effectiveness. As the final THE UEFA EURO 2012 ANTI-DOPING PROGRAMME -SCIENTIFIC REVIEW programme at the tournament. This was a significant challenge, with the tournament taking place in two host countries, each with four host cities spread over a wide geographical area, and only one WADA accredited laboratory in the two countries at which to analyse samples.
The tournament's anti-doping programme involved both pretournament out-of-competition testing of competing squads at their preparatory training camps and a full programme of in-competition testing at all matches in the tournament. Testing was supplemented by a pre-tournament education and information programme for participating teams and players.
Applicable rules
The UEFA Anti-Doping Regulations comply with those of FIFA, as well as the standards established by the WADA. These regulations were in force at the tournament. For the purposes of WADA's Prohibited List, UEFA regulations specify that the tournament's incompetition period commences 24 hours before the first match of the tournament and ends 24 hours after the final match. This meant that all pre-tournament samples were analysed on the basis of an out-of-competition analytical menu and all tournament samples (including those collected between matches) were analysed on the basis of an in-competition analytical menu. Anti-doping rule violations (ADRVs) and associated penalties were as specified in FIFA's regulations and the World Anti-Doping Code (WADC) [1] .
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Sample collection kit
Collecting and transporting samples, particularly blood samples, always presents a unique challenge, with the need to ensure that the integrity of samples is maintained during the journey from the collection site to the laboratory. This is particularly difficult where travel over longer distances is required. The kit used has to be reliable, trusted by the players and teams, and -perhaps most importantly -easy for DCOs and BCOs to use, store and transport.
All sample collection kits and associated equipment used in connection with the tournament were supplied by the company Berlinger from Switzerland, which also supplies kits for UEFA's annual anti-doping programme. Berlinger is one of the leading suppliers of equipment for anti-doping programmes in international sport.
Urine and blood samples were collected using standard Berlinger Bereg kits. Blood samples were taken with a butterfly needle. Four separate tubes were needed for whole blood and serum in order to store all of the samples (an "A" and "B" sample for each). As blood and serum samples need to be analysed shortly after collection, and must be kept at a very stable temperature (between 4 and 12°C), cooling equipment was required to maintain this temperature for at least 48 hours. The Nanocool box was used for this purpose for all tournament and pre-tournament blood and serum samples, with a Q Tag device to monitor the temperature during transit. Nanocool boxes were prepared by BCOs for out-of-competition testing and by the Warsaw laboratory for in-competition testing. All blood samples were securely refrigerated in the doping control station until the collection of samples had been completed, at which point the Nanocool box was activated by the BCO.
Management of Therapeutic Use Exemptions (TUEs)
Management of TUEs followed UEFA's usual procedure, which complies with WADA's International Standard for TUEs [3] . All TUE applications for players had to be submitted to UEFA 21 days before the start of the tournament (with the exception of emergency cases, which could be reviewed at shorter notice if they occurred just prior to the start of the tournament).
Between 1 May 2012 and 2 July 2012, UEFA granted one TUE for glucocorticosteroids. This was the only TUE applied for in connection with the tournament.
Out-of-competition testing programme
The test distribution plan for the pre-tournament programme was complicated by a combination of (i) the unique legal arrangements in European football, whereby UEFA has jurisdiction over players only when they are competing in its competitions, and (ii) the short period of time that teams had to prepare for the tournament after the completion of their domestic club seasons. In effect, a three week window was available in which to conduct out-of-competition doping controls. This was the time between the point at which selected players met for pre-tournament training for the first time and the point at which teams left their training camps for the host coun- 
Sample collection and analysis
Following a recommendation by the UEFA Anti-Doping Expert Panel, the UEFA Executive Committee decided that both blood and urine samples should be collected at each doping control, both prior to and during the tournament. This was a continuation of the policy adopted at the 2008 tournament, which had been the first time that both blood and urine analysis had been implemented at a major international sports event. In total, 284 players were tested in connection with the 2012 tournament on the basis of an analytical menu that was devised by experts from leading WADA accredited laboratories in Europe and approved by the UEFA Anti-Doping Expert Panel. The menu included partial screening for out-of-competition samples and, in addition, testing for artificial haemoglobin, blood transfusion (whole blood), blood parameters (whole blood), hGH (serum), EPO (urine), CERA (serum), [4, 5, 6, 7] SARMS (urine -as part of the partial OOC screen) and plasticisers (urine), as well as IRMS analysis (which can identify endogenous and exogenous intake of anabolic steroids, providing a complete individual steroid profile).
All out-of-competition doping controls conducted pre-tournament involved ten players from the team undergoing blood, urine and serum tests with no notice at the team's pre-tournament training camp. All participating teams were visited at least once prior to the start of the tournament, and a total of 160 tests were administered (Table 2) hours of collection and were analysed within 48 hours of receipt (with the exception of IRMS analysis, which was conducted within 96 hours) ( Table 3 ). All samples collected in the out-of-competition programme came back negative.
In-competition testing programme
Doping controls were conducted after every match at the tournament, with two players from each team drawn to undergo testing, plus two reserves. Reserves were available to be tested in the event that a selected player sustained an injury that rendered him incapable of completing the test (which did not occur at any tournament match). Any of the 23 squad players could be drawn for testing, regardless of whether they actually participated in the match. the Lausanne laboratory. Training was also offered by manufacturers providing new analytical equipment. Table 6 summarises the pH and specific gravity of the urine samples (A samples) collected during in-competition and out-of-competition testing.
Pre-analytics
Urine testing
Out-of-competition urine samples were tested for the following The distribution of testosterone to epitestosterone (T/E) ratios in out-of-competition and in competition samples is shown in Figure 1 and Figure 2 .
All samples with a T/E ratio in excess of 4.0 were analysed using IRMS in accordance with the requirements laid down in the WADA All 124 players' blood and urine samples collected in the incompetition programme were returned as negative. On three occasions, blood could not be successfully collected from a player (with two of these incidents involving the same player). Following the conclusion of the tournament, all samples were placed in storage (at -20°C) and will be retained for re-analysis by UEFA as required.
Transport to the laboratory
Overview of the delivery conditions of IC samples (standard four blood and four urine samples per match) to the Warsaw laboratory is presented in Table 5 .
Results and discussion
Sample analysis
In accordance with WADA's quality control requirements, tournament samples were analysed to the highest possible standards.
Analysts working in the laboratory in Warsaw were trained prior to the tournament in the Lausanne and Seibersdorf laboratories, and pre-tournament training was conducted in Warsaw by experts from International Standard for Laboratories [11, 12, 13] . No indication of the use of synthetic testosterone or testosterone precursors was identified. The Warsaw laboratory also sent all steroid profile parameters to UEFA in order to compare those results with the results of previous analysis.
The presence of recombinant erythropoietin was tested for using ultrafiltration, isoelectric focusing (IEF), double blotting and chemiluminescence detection [14, 15, 16, 17] . For suspicious profiles, an SDS PAGE test was conducted straight after screening [18] . All results were negative. The percentage of samples with suspicious profiles was approximately 19% for out-of-competition samples and approximately 6% for in-competition samples.
Each of the OOC samples was analysed for the presence of plasticiser metabolites [19] . Although the presence of elevated levels of these indicators is not unambiguous proof of the use of blood transfusion, this represents important additional evidence alongside the blood passport programme [20] . No suspicious results were detected.
Blood parameter distribution
Blood parameters were only analysed in the out-of-competition programme. A full blood count was obtained for all blood samples, and the stimulation index (OFF score) and abnormal blood profile score (ABPS) were calculated [21, 22, 23] . Blood parameters were This had led to elevated levels of some parameters, meaning that the analysis was of little value ( Figure 3, Figure 4 , Figure 5 ). The conditions required for athlete blood passport (ABP) tests were not fulfilled either, as players were not required to rest for two hours post-match.
Blood parameters are determined in a harmonised manner thanks to an external quality control programme for blood samples in which all WADA-accredited laboratories participate [25] . All laboratories use the same protocol and quality controls to ensure that results can be interpreted consistently and compared across laboratories. All blood parameters from samples collected in connection with UEFA EURO 2012 were sent to UEFA by the Warsaw laboratory to allow comparison with previous results.
Growth hormone testing
Serum was tested for the presence of human growth hormone in both the out-of-competition and in-competition programmes (Table 7 ).
All HGH tests were prepared using a special chemiluminescence immunoassay kit for HGH [26] . All results were expressed by means of two measured concentrations: the concentration resulting from the "REC" assay (corresponding roughly to the recombinant HGH) and the concentration resulting from the "PIT" assay (corresponding to all HGH forms circulating in the blood). The ratio of the two concentrations was calculated in accordance with WADA guidelines [27] . Only negative samples were observed.
Non-steroidal anti-inflammatory drugs (NSAIDs)
NSAIDs were detected in a large number of samples, both incompetition and out-of-competition. A relationship was found between the duration of the tournament and the number of samples containing NSAIDs. The most frequent compound was diclofenac, which was used more towards the end of the tournament.
Nicotine
Very high concentrations of nicotine were observed in several samples. This high concentration is very rarely observed in routine anti-doping samples.
Declaration of medication
As is standard practice for doping controls, players were required to declare any medication that had recently been taken or administered prior to the control. Of the 124 players tested at the tournament, 65 (52%) declared that they had taken some sort of medicine during the last three months, while 59 (48%) declared that they had not taken any medicine, or only vitamins or minerals.
Of the players who declared the recent use of medication, 4% declared that they had been given a local cortisone injection during the last three months and 54% (i.e. 35 of those 65) declared that they had taken (or were taking) NSAIDs. Thus, 28% of the players tested at the tournament had taken NSAIDS during the previous three months.
These findings suggest that treatment of musculoskeletal problems with local corticosteroids is uncommon in football, whereas treatment with NSAIDs is more frequent. However, the figure for NSAIDs is lower than at UEFA EURO 2008, where 44% of players tested reported having taken NSAIDs.
10% of the players tested declared that they had taken sleeping pills on account of insomnia during the last three months.
Conclusion
The anti-doping programme conducted at UEFA EURO 2012 con- 
